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Immunocompromised patients are at risk of
developing Epstein-Barr virus (EBV)-related lym-
phoproliferative disorders. Quantitative determi-
nation of serum EBV DNA permits early diagno-
sis of an AIDS-related non-Hodgkin’s lymphoma,
and surveillance of treatment response and/or
relapse, and thus may be a useful tool to monitor 
disease activity.
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Immunocompromised patients are at risk to
develop Epstein-Barr virus (EBV)-associated lym-
phoproliferative disorders and lymphoma. The
incidence of non- Hodgkin’s lymphoma (NHL) is
increased approximately 100-fold in patients with
advanced human immunodeficiency virus (HIV)
infection [1]. Diagnosis is often difficult in early
stages, even with modern imaging technology. We
report how quantitative assessment of EBV DNA
in serum contributed to the diagnosis and follow-
up of a NHL in a HIV-infected patient.
Summary
No financial sup-
port declared.
Introduction
Case report
A 63-year-old man with haemophilia A had become
infected with HIV and hepatitis C, known since 1986 and
1989 respectively. He had a history of diffuse infiltrative
lymphocytosis syndrome with bilateral parotid gland
swelling (1992) and lymphoid interstitial pneumonitis,
which was successfully treated with prednisone (autumn
1999). In January 2001 he presented with fever in the
evening, weight loss (5 kg within 3 months), normocytic
anaemia (haemoglobin 102 g/L) and rising levels of C-re-
active protein (CRP). A chest X-ray was normal, blood and
stool cultures remained negative. A computed tomogra-
phy (CT) revealed multiple retroperitoneal lymph nodes
(diameter ~15 mm). His CD4 lymphocyte count was 186
 106/L (normal: >500  106/L), the HIV-1 RNA level was
1000 copies/ml. Based on HIV resistance testing, the an-
tiretroviral therapy was changed from zidovudine, didano-
sine and efavirenz to abacavir, lamivudine and lopinavir/
ritonavir. This resulted in sustained full suppression of
HIV RNA blood levels and CD4 counts around 50–200 
106/L, fever and persisted weight loss. A repeated abdom-
inal CT after three months was unchanged. Serum IgM
against EBV early antigen and IgG against EBV nuclear
antigen were detected, indicating EBV reactivation. A
quantitative real-time polymerase chain reaction (PCR)
assay as recently described [2], revealed serum EBV DNA
levels that gradually increased over the next months (fig-
ure 1). A 14-day course of oral valacyclovir 1.0 g t.i.d. was
unsuccessful, as EBV DNA levels gradually increased up
to 3685 copies/ml. The patient deteriorated, developed
jaundice and was hospitalised (September 2001). CT now
showed progressive enlargement of retroperitoneal lymph
nodes of 20 mm in diameter and hepatomegaly without
focal lesions. A biopsy of a retroperitoneal lymph node
showed immunoblastic lymphocytes positive for CD20 (B
cells), the expression of the EBV-encoded latent mem-
brane protein 1 and the expression of Ki-67 >80%, indi-
cating an extensive proliferation rate. The diagnosis of a
HIV-associated large cell high grade NHL was made and
a cytostatic treatment with cyclophosphamide, doxoru-
bicine, vincristine and prednisone (CHOP regimen) was
started (figure 1). Within two weeks the patient’s condi-
tion improved markedly. Fever, jaundice and inflamma-
tory parameters disappeared. In November, after the third
of six chemotherapeutic cycles, the enlarged lymph nodes
had completely disappeared on the abdominal CT scan
and serum EBV DNA levels fell below the limit of detec-
tion (<100 copies/ml). Cytostatic treatment was com-
pleted until January 2002. In March, fever in the evening
relapsed accompanied by increasing serum EBV DNA
levels and normocytic anaemia. CT revealed enlarged
EBV DNA in serum 264
retroperitoneal lymph nodes, which prompted a new cy-
tostatic treatment with cyclophosphamide, doxorubicin
and prednisone between June and September 2002, with-
out significant clinical improvement. A humanized anti-
CD 20 monoclonal antibody (rituximab) treatment (four
cycles from December 2002 to March 2003) caused a
marked improvement. Serum EBV DNA levels fell again
below the detection limit. In April 2003 serum EBV DNA
levels increased again, preceding the clinical relapse with
fever, jaundice and progressive deterioration of the gen-
eral condition. The patient died in July 2003 in hepatic
failure. No autopsy was performed.
Method
Quantitative DNA analysis was performed using the
TaqMan® (Applied Biosystems, Rotkreuz, Switzerland)
real-time PCR technique. PCR primers and probe were
selected for the amplification of a 101 base pair sequence
in the conserved BamHI W region of the EBV genome,
as reported [2]. Briefly, DNA extracted from 1 ml serum
was amplified with 40 cycles of 15 sec. at 95 °C and 60 sec.
at 60 °C in an ABI prism 7700 sequence detector using the
Discussion
EBV-associated lymphoproliferative disorders
and lymphoma are a major risk for immunocom-
promised HIV-infected patients [1]. Highly active
antiretroviral therapy (HAART) has contributed
to the improved survival rate of patients with HIV
infection but has not significantly decreased the in-
cidence of NHL, in contrast to the reduced inci-
dence of Kaposi sarcoma and primary NHL of the
central nervous system [3, 4]. The development of
quantitative PCR assays permits to monitor the
HIV infection and to correlate the serum EBV
DNA level with the EBV disease activity, thereby
monitoring patients at risk for EBV-associated
lymphoproliferation [2, 5–7]. 
In our patient gradually rising serum EBV
DNA levels preceded the clinical detection of the
NHL by months. These serum EBV DNA levels
correlated well with the EBV disease activity, ie
lymphoma. Their time course permitted to mon-
itor and navigate the treatment. Monitoring of
EBV DNA levels in blood has been shown to be
useful in the diagnosis and management of post-
transplant lymphoproliferative disease (PTLD)
and other EBV-associated malignancies [8, 9].
However, its predictive value in HIV-infected in-
dividuals has been questioned [6, 10]. Most data 
on EBV burden in HIV patients, treated with
HAART or not, are based on EBV levels in periph-
eral blood mononuclear cells (PBMC) and de-
scribe high EBV DNA levels in the majority of
HIV infected patients. These high levels result
from the expanded pool of EBV-infected cells in
these immunocompromised hosts, but do not dis-
criminate patients with AIDS-associated NHL
from those without it [6, 10–12]. Our case report
suggests that this may be different by following
serum levels of EBV DNA, since they heralded the
NHL and correlated throughout with the disease
Figure 1
Serum levels of EBV
DNA measured with
a real-time poly-
merase chain reac-
tion assay in a HIV-
positive haemophilic
patient. A continuous
rise was observed
despite an intermit-
tent valacyclovir
(VCV) treatment.
Nine months later an
EBV-associated large
B-cell lymphoma was
diagnosed, followed
by chemotherapy
(CHOP), with a com-
plete disappearance
of the serum EBV
DNA and later reap-
pearance during
relapse. A second
chemotherapy
(cyclophosphamide
and doxorubicin) 
had no effect,
whereas rituximab
caused a disappear-
ance again, followed
by a new relapse
before the patient’s
death.
TaqMan 2 Universal Master Mix (Applied Biosystems)
with 300 nM of each primer and 200 nM of the probe.
Each sample was analysed in triplicate, positive and nega-
tive controls were included in every run. A pUC18 plas-
mid containing the EBV BamHI W fragment was included
in every PCR run and served as internal control, and was
used in the calibration curve based on which the EBV
DNA copies were quantified. 
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activity. Serum EBV DNA levels indeed have been
shown to correlate with EBV disease activity [2, 6,
8, 9] showing a similar sensitivity, but higher speci-
ficity than its levels in PBMC from the same pa-
tients [8]. Although these findings were not con-
firmed in other studies, serum EBV DNA levels
permitted the detection of NHL patients also in
immunocompromised hosts [10, 13]. 
Some of this controversy may be explained by
the different pathogeneses of AIDS-NHL. They
include on the one hand Burkitt’s lymphoma (BL),
which may develop in hosts with a relatively pre-
served immune function, and which is character-
ized by consistent c-myc activation and EBV in-
fection in approximately 30%. On the other hand,
immunoblastic lymphomas are found only in se-
verely immunodeficient hosts and are associated
with EBV in >90%. In contrast to BL, im-
munoblastic lymphomas express consistently the
EBV-encoded latent membrane protein 1, known
to function as a viral oncogene. The recent obser-
vation that the EBV DNA in the serum of patients
with lymphomas and nasopharyngeal carcinomas
consists of short DNA fragments [14] suggests that
these DNA molecules are released by apoptosis of
cancer cells and are not the product of viral repli-
cation. This is another argument in favour of quan-
tifying EBV DNA in serum rather than in PBMC.
Pre-emptive treatment of EBV-associated dis-
ease in HIV-infected patients according to EBV
DNA serum levels has not been examined. As in
PTLD, monitoring of EBV DNA may be useful to
enable a prompt rather than pre-emptive treat-
ment [15].
The current literature does not identify the
best specimen to sample for monitoring of EBV
levels in patients at risk. Serum EBV DNA levels
are easier to interpret and clinically more useful
because EBV DNA is not detected in serum of
healthy carriers in contrast to PBMC. Moreover,
the levels of serum EBV DNA are independent of
the leukocyte count in these frequently cytopenic,
immunocompromised patients. 
Although large series of patients are needed to
confirm the findings of this case, we propose to
monitor HIV-infected patients at risk for EBV-
associated lymphoproliferation by measuring EBV
DNA levels in serum. 
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